INFANT A research centre focused entirely on pregnancy, birth and early childhood. Hosted at University College Cork (UCC), Cork, Ireland, The Irish Centre for Maternal and Child Health Research has local impact with a global reach. INFANT is answering the international need for research and innovation to improve health outcomes for mothers and babies. Across pregnancy, birth, infancy and childhood, INFANT is solving challenges through its key research themes
(John Wiley & Sons, Inc., 2021-07-28) Fernandez-Rivas, Montserrat; Vereda, Andrea; Vickery, Brian P.; Sharma, Vibha; Nilsson, Caroline; Muraro, Antonella; Hourihane, Jonathan O'B.; DunnGalvin, Audrey; du Toit, George; Blumchen, Katharina; Beyer, Kirsten; Smith, Alex; Ryan, Robert; Adelman, Daniel C.; Jones, Stacie M.; Aimmune Therapeutics
Background: The benefit of daily administration of Peanut (Arachis hypogaea) Allergen Powder-dnfp (PTAH)-formerly AR101-has been established in clinical trials, but limited data past the first year of treatment are available. This longitudinal analysis aimed to explore the impact of continued PTAH therapeutic maintenance dosing (300 mg/day) on efficacy, safety/tolerability, and food allergy-related quality of life.Methods: We present a subset analysis of PALISADE-ARC004 participants (aged 4-17 years) who received 300 mg PTAH daily for a total of similar to 1.5 (Group A, n = 110) or similar to 2 years (Group B, n = 32). Safety assessments included monitoring the incidence of adverse events (AEs), accidental exposures to food allergens, and adrenaline use. Efficacy was assessed by double-blind, placebo-controlled food challenge (DBPCFC); skin prick testing; peanut-specific antibody assays; and Food Allergy Quality of Life Questionnaire (FAQLQ) and Food Allergy Independent Measure (FAIM) scores.Results: Continued maintenance with PTAH increased participants' ability to tolerate peanut protein: 48.1% of completers in Group A (n = 50/104) and 80.8% in Group B (n = 21/26) tolerated 2000 mg peanut protein at exit DBPCFC without dose-limiting symptoms. Immune biomarkers showed a pattern consistent with treatment-induced desensitization. Among PTAH-continuing participants, the overall and treatment-related exposure-adjusted AE rate decreased throughout the intervention period in both groups. Clinically meaningful improvements in FAQLQ and FAIM scores over time suggest a potential link between increased desensitization as determined by the DBPCFC and improved quality of life.Conclusions: These results demonstrate that daily PTAH treatment for peanut allergy beyond 1 year leads to an improved safety/tolerability profile and continued clinical and immunological response.